Mr. Miguel Martin reports

AURORA CANNABIS CORRECTS INACCURATE STATEMENTS MADE IN SUPPORT OF CURALEAF HOLDINGS' HOSTILE BID

Aurora Cannabis Inc. has cautioned shareholders that Curaleaf Holdings Inc.'s announcement of an unsolicited takeover bid appears to contain inaccurate statements about Aurora's business and should be viewed skeptically.

Aurora's board of directors, together with a newly formed special committee of independent directors, is reviewing Curaleaf's proposal in consultation with financial and legal advisers to determine the course of action that best serves the interests of the company and its shareholders.

Shareholders are advised to take no action with respect to the Curaleaf offer at this time.

"Curaleaf's timing and public comments appear to be a transparent attempt to pressure Aurora shareholders into making a short-term decision for the benefit of Curaleaf shareholders," said Miguel Martin, executive chairman and chief executive officer of Aurora. "Curaleaf's interest underscores the value that Aurora has created. They are trying to acquire our world-class EU GMP global infrastructure at the lowest possible price, depriving our shareholders of the long-term value our strategy is built to deliver.

"This opportunistic hostile bid comes as Aurora's multiyear transformation into a high-margin, global medical cannabis leader is yielding positive results. With three consecutive years of positive adjusted EBITDA, accelerating international sales and our recent expansion into the critical U.K. market, Aurora is reaching a pivotal inflection point," Mr. Martin added.

"The company's special committee of the board has not yet made a formal recommendation regarding the offer. Aurora will not let inaccurate statements about the company stand uncorrected while the review is under way. The special committee and board are focused on protecting shareholder investment and ensuring full value is realized," Mr. Martin concluded.

Setting the record straight

Curaleaf has made several public claims regarding Aurora's operational and market performance that do not accurately or fully reflect the company's business model or actual financial results:

• Response and engagement to the offer: As Curaleaf acknowledged in its hostile bid circular, Aurora has had several discussions with Curaleaf since June, 2026, most recently on Aug. 12. Discussions included Aurora's lead independent director and the executive chairman and CEO. Curaleaf's public statements appear to de-emphasize these repeated engagements.
• International medical market performance:
  • German market remains a major driver of international growth:
    • Germany is a key driver of Aurora's 17-per-cent year-over-year international net revenue growth in fiscal first quarter 2027, compared with the prior-year quarter as the company continues to expand its medical cannabis business in that market.
    • Curaleaf claims that regulatory changes to German medical reimbursement are contributing to a major challenge for Aurora. This is incorrect: The reimbursement market segment accounted for less than 10 per cent of Aurora's total German volume prior to these changes.
  • United Kingdom market position and growth opportunities:
    • Aurora is gaining share in the U.K., where patients have consistently preferred its high-quality products.
    • On Aug. 19, 2026, Aurora strengthened its position by acquiring Internode Pharma Ltd. and HAP Pharma Ltd., expanding direct distribution in Europe's fastest-growing medical market.
  • Aurora continues to be a market leader in Poland:
    • Aurora continues to hold the No. 1 market share position by revenue in Poland.
    • Increases in annual import limits and a loyal patient base strengthen Aurora's growth outlook in this key, highly regulated market.
• Financial strength refutes Curaleaf's claims:
  • Aurora's recent financial performance demonstrates a stronger, more focused business than Curaleaf's characterization suggests.
  • Aurora delivered record global medical cannabis revenue and adjusted earnings before interest, taxes, depreciation and amortization results in fiscal 2026.
  • Momentum continues, with year-over-year growth in international net revenue and industry-leading adjusted gross margins before FV adjustments.
  • These strong results reflect Aurora's strategy of prioritizing global medical cannabis growth, including exiting the lower-margin plant propagation and Canadian consumer businesses.
• Curaleaf's cultivation claims ignore the strength of Aurora's facilities:
  • Curaleaf's comments on Aurora's cultivation methods and output per square foot are inaccurate and outdated, and do not reflect the strength of Aurora's cultivation facilities.
  • Aurora has built specialized expertise in manufacturing facilities that cannot be easily replicated. Through years of operating large-scale European Union good-manufacturing-practice-certified facilities, Aurora has developed the scientific, cultivation, regulatory and operational capabilities that support its global medical cannabis strategy.
  • Aurora is pro-actively expanding capacity to support international growth and ensure consistent supply as regulatory standards tighten and patient demand grows.
  • Over the past five years, Aurora has increased its EU GMP production capacity by more than 40 per cent and continues to invest further, including through capacity added in the Safari Flower Company transaction.

Aurora shareholders are advised to take no action with respect to the Curaleaf offer at this time.

Aurora shareholders with questions about the offer or who would like to stay informed may contact Aurora's strategic adviser and information agent:

Kingsdale Advisors:

• Toll-free (within North America): 1-800-749-9052;
• Call or text: 416-623-4172;
• E-mail: contactus@kingsdaleadvisors.com.

About Aurora Cannabis Inc.

Aurora is a global leader in medical cannabis, dedicated to improving lives through scientific expertise, proven performance and a deep commitment to patient care. Aurora serves medical markets across Canada, Europe, Australia and New Zealand with a portfolio of trusted, leading brands including Aurora, MedReleaf, Pedanios, IndiMed, San Raf and Whistler Medical Marijuana Corp. With world-class GMP-certified manufacturing facilities in Canada and Germany, and a team of industry-leading professionals, Aurora continues to expand its global footprint and deliver consistent, high-quality cannabis products with the purpose of opening the world to cannabis.

Aurora's common shares trade on Nasdaq and the Toronto Stock Exchange under the symbol ACB.

We seek Safe Harbor.